Investing.comCodex · 实盘重复把握 6/10
北京时间·🕒 发布 13:04:37时区推断·⟳ 抓取 13:05:15·⚡ 决策 07-27 13:08:21 +3m06s·92.2 天前
argenx拟以22亿美元现金收购Forte Biosciences，报价77美元/股
Forte Biosciences（FBRX.US）收到每股77美元全现金要约，较7月24日收盘54.78美元仍有约40.6%的静态上行空间。
📄 原文Investing.com↗ 原文
argenx to acquire Forte Biosciences for $2.2 billion in cash
Oil tumbles over 5% as U.S.-Iran pause sparks hopes for diplomatic breakthrough AMSTERDAM and DALLAS - argenx (Euronext…
▼ 亏 -0.35%入场 07-27 盘前首笔 @76.60 → 离场 07-28 常规开盘 @76.50
决策后走势暂无图(这条腿还没有复盘打分的日线切片)
💡 交易逻辑77美元现金收购价差未补齐则做多套利
怎么买 限价买入 不高于 70、仅下一个交易日，不成交作废
怎么卖 止盈 +6%(半仓)/+9%(清仓) · 止损 -10% · 时间止损 5日
不做 argenx（ARGX.US）
收购方支付22亿美元现金补强管线，但相对其现金与业务体量短线方向不够清晰，不做主标的。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 FBRX.US Forte Biosciences
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 FBRX.US Forte Biosciences
| 收益状态 | -0.35% 已平仓 |
|---|---|
| 进场成交 | 2026-07-27 · 盘前首笔 · 07-27 16:01 北京 · @76.5976 |
| 离场成交 | 2026-07-28 · 常规开盘 · @76.5 |
| 毛收益 | -0.13% |
| 成本 | +0.23% |
| 净收益 | -0.35% |
| 计入收益 | -0.36% |
| 计入 | 同日重复,不计入曲线 |
| 建仓日 | 2026-07-27 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 17:56
研究档案
消息传播链
- Forte披露FB102白癜风Phase 1b积极结果，这是收购溢价口径提到的前序重估催化。市场反应:FBRX 7月9日收盘+78.3%，7月10日续涨约19.7%。
- 报道argenx将以每股77美元现金收购Forte，总股权价值约22亿美元，预计2026年三季度完成。市场反应:美股尚未开盘，连续成交不可用。
- 收购消息前最后收盘价约54.66美元，市值约11.2亿美元，低于77美元要约价。市场反应:按77美元要约价测算静态价差约40.8%。
关键理由
- Forte Biosciences（FBRX.US）收到每股77美元全现金要约，较7月24日收盘54.78美元仍有约40.6%的静态上行空间。
- 交易由argenx现金支付、无融资条件，双方董事会已批准，预计2026年三季度完成，结构上更接近现金收购套利而非临床数据追涨。
- FB102此前7月9日Phase 1b白癜风数据已推动FBRX大涨，本次收购是新增确定性退出事件；若开盘未一步贴近77美元，存在剩余价差交易窗口。
主要风险
- FBRX已在7月9日临床数据后从约20美元区间涨至54.78美元，事件前已有明显抢跑，开盘可能直接跳至接近77美元导致价差不足或无法成交。
- 仍需满足多数股份 tender、HSR等待期等交割条件；若监管或股东接受度出问题，现金收购套利会快速回撤。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-09 · 影响 weakens
AppliedXL指出样本量较小且部分响应率口径受单个安慰剂患者影响，削弱FB102基本面确定性，但现金收购交易中主要风险转为交割风险。
检索:Forte Biosciences FB102 Phase 1b vitiligo concerns placebo small sample July 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-27 · 影响 weakens
报道称交易无融资条件，但仍需多数股份 tender 与HSR等待期，属于常规但真实的交割条件。
检索:argenx Forte Biosciences acquisition financing condition cash tender offer HSR majority tender 原文 ↗
历史先例(按相似度)
- 相似度 9/10 DAWN 2026-03-06 Servier以21.50美元/股现金收购Day One,总股权价值约25亿美元,较前收盘溢价约68%,需多数股份 tender 及反垄断条件。 原文 ↗
测DAWN在2026-03-06正式收购公告后的+1/+3/+5日反应。
相似度依据:同为美国上市生物科技公司被欧洲药企以全现金要约收购,交易额2.5亿美元量级与当前22亿美元接近,锚点为正式签约公告日。 - 相似度 9/10 FUSN 2024-03-19 AstraZeneca以21.00美元/股现金加3.00美元CVR收购Fusion, upfront交易价值约20亿美元,较前收盘溢价97%。 原文 ↗
测FUSN在2024-03-19正式收购公告后的+1/+3/+5日反应。
相似度依据:同为美国/纳斯达克临床期生物科技被大型药企现金收购, upfront约20亿美元与当前22亿美元高度接近,且同含潜在CVR套利定价。 - 相似度 8/10 INBX 2024-01-23 Sanofi以30.00美元/股现金、5.00美元CVR及New Inhibrx股份收购INBRX-101相关资产,总价值最高约22亿美元。 原文 ↗
事件后 +1日 -13.0% · +2日 -0.9% · +3日 +1.6% · +4日 +12.6% · +5日 +7.6%
相似度依据:同为美国生物科技资产/公司出售给大型药企,总对价最高约22亿美元与当前完全同量级,但结构含spin-off和CVR,现金套利口径更复杂。 - 相似度 8/10 ETNB 2025-09-18 Roche以14.50美元/股现金加最高6.00美元CVR收购89bio,总股权价值最高约35亿美元,现金部分约24亿美元。 原文 ↗
测ETNB在2025-09-18正式收购公告后的+1/+3/+5日反应。
相似度依据:同为美国临床阶段生物科技被欧洲大药企收购,现金加CVR总对价最高35亿美元,规模略高但机制接近。 - 相似度 8/10 CBAY 2024-02-12 Gilead以32.50美元/股现金收购CymaBay,总股权价值约43亿美元,较前收盘溢价27%,一季度完成。 原文 ↗
测CBAY在2024-02-12正式收购公告后的+1/+3/+5日反应。
相似度依据:同为美国生物科技被大药企以全现金 tender offer 收购,但交易额43亿美元高于当前且标的有接近获批资产,确定性更高。 - 相似度 7/10 CPRX 2026-05-07 Angelini Pharma以31.50美元/股现金收购Catalyst Pharmaceuticals,总股权价值约41亿美元,进入美国罕见病/脑健康市场。 原文 ↗
事件后 +1日 -0.1% · +2日 -0.1% · +3日 -0.1% · +4日 -0.0% · +5日 -0.0%
相似度依据:同为美国上市药企被欧洲药企全现金收购,但Catalyst为商业化公司且交易额41亿美元,目标风险与FBRX临床期标的不同。 - 相似度 7/10 RYZB 2023-12-26 Bristol Myers Squibb以62.50美元/股现金收购RayzeBio,总股权价值约41亿美元,为放射性药物平台收购。 原文 ↗
测RYZB在2023-12-26正式收购公告后的+1/+3/+5日反应。
相似度依据:同为纳斯达克创新药公司被大药企全现金收购,但RayzeBio交易额约41亿美元、上市时间短且溢价后几乎直接锚定现金价。 - 相似度 7/10 TSVT 2025-03-10 Bristol Myers Squibb以5.00美元/股全现金收购2seventy bio,总股权价值约2.86亿美元,较前收盘溢价88%。 原文 ↗
测TSVT在2025-03-10正式收购公告后的+1/+3/+5日反应。
相似度依据:同为美国生物科技现金收购套利,但交易额仅2.86亿美元,规模显著小于当前且为单一商业化资产回收型交易。 - 相似度 6/10 MOR 2024-02-05 Novartis以68.00欧元/股现金要约收购MorphoSys,要约价较未受影响三个月VWAP溢价142%。 原文 ↗
测MOR在2024-02-05收购协议公告后的+1/+3/+5日反应。
相似度依据:同为欧洲大药企收购公开上市生物科技,但被收购标的是德国上市公司且A股/美股交易机制不同,用于方向类比而非涨幅校准。 - 相似度 5/10 POLN 2026-07-21 Samsung Biologics拟以44.30瑞士法郎/股现金收购PolyPeptide,总价值约18亿美元,此前已有收购传闻抢跑。 原文 ↗
测POLN在2026-07-21正式收购公告后的+1/+3/+5日反应。
相似度依据:同为生命科学公司现金收购且交易额18亿美元接近当前,但PolyPeptide为瑞士CDMO/制造商,不是临床生物科技标的。
原文全文
展开原文 · 2,250 字
Oil tumbles over 5% as U.S.-Iran pause sparks hopes for diplomatic breakthrough
AMSTERDAM and DALLAS - argenx (Euronext & Nasdaq:ARGX) announced today that it has entered into a definitive agreement to acquire Forte Biosciences, Inc. (Nasdaq:FBRX) for $77 per share in cash, representing a total equity value of approximately $2.2 billion, according to a press release statement.
The acquisition price represents a premium of approximately 86% to Forte Biosciences’ volume-weighted average price since the company reported positive Phase 1b data in vitiligo on July 9, 2026.
The transaction centers on FB102, Forte Biosciences’ lead program, a first-in-class anti-CD122 antibody. Forte Biosciences recently reported positive Phase 1b data in vitiligo, demonstrating statistically significant treatment benefit. The company also reported positive Phase 1b data in celiac disease last year, with Phase 2 data expected in the second half of this year.
Under the terms of the merger agreement, argenx will commence a cash tender offer to acquire all outstanding shares of Forte Biosciences common stock through a wholly owned subsidiary. The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The transaction will be funded entirely from cash on hand and is not subject to a financing condition. The boards of directors of both companies have approved the transaction, which is expected to close in the third quarter of 2026.
FB102 is an anti-CD122 antibody that targets pathogenic T-cell and NK-cell activity. Beyond celiac disease and vitiligo, the drug candidate has potential applications in alopecia areata and additional autoimmune diseases.
Goldman Sachs International is serving as exclusive financial advisor and Freshfields LLP is serving as legal advisor to argenx. Guggenheim Securities is serving as exclusive financial advisor and Wilson Sonsini Goodrich & Rosati is serving as legal counsel to Forte Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
AMSTERDAM and DALLAS - argenx (Euronext & Nasdaq:ARGX) announced today that it has entered into a definitive agreement to acquire Forte Biosciences, Inc. (Nasdaq:FBRX) for $77 per share in cash, representing a total equity value of approximately $2.2 billion, according to a press release statement.
The acquisition price represents a premium of approximately 86% to Forte Biosciences’ volume-weighted average price since the company reported positive Phase 1b data in vitiligo on July 9, 2026.
The transaction centers on FB102, Forte Biosciences’ lead program, a first-in-class anti-CD122 antibody. Forte Biosciences recently reported positive Phase 1b data in vitiligo, demonstrating statistically significant treatment benefit. The company also reported positive Phase 1b data in celiac disease last year, with Phase 2 data expected in the second half of this year.
Under the terms of the merger agreement, argenx will commence a cash tender offer to acquire all outstanding shares of Forte Biosciences common stock through a wholly owned subsidiary. The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
The transaction will be funded entirely from cash on hand and is not subject to a financing condition. The boards of directors of both companies have approved the transaction, which is expected to close in the third quarter of 2026.
FB102 is an anti-CD122 antibody that targets pathogenic T-cell and NK-cell activity. Beyond celiac disease and vitiligo, the drug candidate has potential applications in alopecia areata and additional autoimmune diseases.
Goldman Sachs International is serving as exclusive financial advisor and Freshfields LLP is serving as legal advisor to argenx. Guggenheim Securities is serving as exclusive financial advisor and Wilson Sonsini Goodrich & Rosati is serving as legal counsel to Forte Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。